OPEN ACCESS Freely available online

Andrology: Open Access

ISSN: 2167-0250

Commentary

# Medication for Heart Resynchronization and Sexual Dysfunction

**Nazia Akbar***

*Department of Andrology, University of Jamia Millia Islamia, New Delhi, India*

## DESCRIPTION

Malignant syndromes like chronic heart failure have a serious impact on a patient's quality of life and functional status. Frequent hospitalizations and severe Quality-of-Life (QoL) deterioration are characteristics of the syndrome's progression. As QoL includes a patient's symptoms, functional abilities, inability to engage in social activities, and subjective perception of health status, it plays a significant role in determining the status of heart failure. When patients and doctors choose between the various therapies options, Quality of Life (QoL) is a crucial factor in advanced heart failure, intermittent inotropic infusion. Studies have shown contradictory findings about their influence on mortality, but they have also shown increases in patients' functional level and quality of life. Patients are more willing to sacrifice quantity for QoL when their heart failure becomes more advanced.

Targeted studies that improve overall understanding of these patients' demands and interventions that evaluate whether they produce desired benefits are necessary for physicians and studies to improve the Quality of Life (QoL) of heart failure patients. The QoL of these individuals will probably be significantly improved by the newly growing field of patient-reported outcomes. Studies have shown that more than 70% of patients with heart failure experience Erectile Dysfunction (ED), which is a factor that negatively affects QoL. These rates appear to occur whether non-ischemic cardiomyopathy or ischemic cardiomyopathy is the underlying cause of the heart failure. The etiology of ED in heart failure is multifaceted, and it is likely influenced by a number of factors, including psychological ones, such as fear of dying, hormone imbalances, and reduced exercise tolerance, and pharmaceutical side effects, positive impact on erectile function in heart failure patients. Cardiac Resynchronization Therapy (CRT) for six months reduced ejection fraction is associated with a considerable reduction in heart failure hospitalizations and death, and CRT is a well-established therapy for patients with heart failure. CRT improves QoL in individuals with heart failure, according to studies. It's significant that QoL after CRT was found to be a separate predictive variable for positive results. The prognosis has been linked to improved QoL after CRT, regardless of the CRT-induced changes in clinical or echocardiographic parameters. There are few studies looking at the impact of CRT on ED. It has been demonstrated that CRT has positive benefits on functional ability, autonomic balance, shear stress, immunoinflammatory state, and arterial blood flow. CRT has not been demonstrated to have negative effects on libido and erectile function, in contrast to other therapies used in the therapy of heart failure. These findings may help to explain CRT-related improvements in left ventricular ejection fraction and functional status were generally followed by an increase in sexual performance.

In particular among older patients, an increasing subset of heart failure patients, ED relates to poor QoL and depression. The impacts of heart failure medicines on QoL, and more specifically on sexual activity, are very helpful and contribute to the development of this area. In the same vein, the effectiveness of overused heart failure therapy strategies, such as fitness training, that enhance performance status and sense of health status and are devoid of serious adverse effects, should be assessed for their effect on sexual performance. Several treatments for heart failure have been developing during the past 20 years. The broad spectrum of QoL components and individualized patient needs and expectations is an important field that is currently under extensive investigation.

**Correspondence to:** Nazia Akbar, Department of Andrology, University of Jamia Millia Islamia, New Delhi, India, E-mail: naziaakbar@gmail.com

**Received:** 01-Mar-2023, Manuscript No. ANO-23-22759; **Editor assigned:** 03-Mar-2023, PreQC No. ANO-23- 22759 (PQ); **Reviewed:** 17-Mar-2023, QC No. ANO-23-22759; **Revised:** 24-Mar-2023, Manuscript No. ANO-23- 22759 (R); **Published:** 31-Mar-2023, DOI:10.35248/2167-0250.23.12.286

**Citation:** Akbar N (2023) Medication for Heart Resynchronization and Sexual Dysfunction. Andrology. 12:286